Pfizer’s reset year starts with a little profit

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.

Read the rest…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks